Skip to main content

Meagan Thistle

FDA building
News
01/28/2025
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
Quiz
Quiz
01/15/2025
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Conference Coverage
12/07/2024
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study presented at the 2024 ASH Annual...
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study presented at the 2024 ASH Annual...
In patients with late-relapse...
12/07/2024
Oncology
Depression
News
11/22/2024
A rstudy presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have...
A rstudy presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have...
A rstudy presented in a poster...
11/22/2024
Psych Congress Network
News
11/15/2022
First batches of D-cycloserine and lurasidone (NRX-101), a phase 3-ready investigational drug targeting suicidal bipolar depression, released.
First batches of D-cycloserine and lurasidone (NRX-101), a phase 3-ready investigational drug targeting suicidal bipolar depression, released.
First batches of D-cycloserine...
11/15/2022
Psych Congress Network
brain imaging
News
05/02/2024
Children who show significant symptoms after head injury are more likely to experience mental and social disturbances and require mental health services, but 23% aren't being evaluated for concussion or brain trauma.
Children who show significant symptoms after head injury are more likely to experience mental and social disturbances and require mental health services, but 23% aren't being evaluated for concussion or brain trauma.
Children who show significant...
05/02/2024
Psych Congress Network
News
12/23/2021
Psych Congress Europe will be held in Barcelona, Spain, February 23-25 and promises to connect the global mental healthcare community with updated approaches in practical psychopharmacology.
Psych Congress Europe will be held in Barcelona, Spain, February 23-25 and promises to connect the global mental healthcare community with updated approaches in practical psychopharmacology.
Psych Congress Europe will be...
12/23/2021
Psych Congress Network
News
04/14/2023
Electroconvulsive therapy (ECT) may be superior to ketamine in treating major depressive episode (MDE) in adults, according to a study published in JAMA Psychiatry. 
Electroconvulsive therapy (ECT) may be superior to ketamine in treating major depressive episode (MDE) in adults, according to a study published in JAMA Psychiatry. 
Electroconvulsive therapy (ECT)...
04/14/2023
Psych Congress Network
Dr Craig Chepke
Exclusive Interview
05/21/2024
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his...
05/21/2024
Psych Congress Network